Kojin Therapeutics shuts down, citing lack of investor interest and complex science
Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan Healthcare Conference in a bind. It needed bridge financing to stay afloat for six months, or it ...
Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan Healthcare Conference in a bind.
It needed bridge financing to stay afloat for six months, or it ...
